Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

2021134 citationsJournal Articlegold Open Access

Authors

Raz Mutai · Rabin Medical Center

Tamar Barkan · Rabin Medical Center

Assaf Moore · Tel Aviv University

Michal Sarfaty · Tel Aviv University

Tzippy Shochat · Rabin Medical Center

Rinat Yerushalmi · Tel Aviv University

Salomon M. Stemmer ·

Abstract

The prognostic impact of HER2-low expression in early-stage luminal disease varies across the genomic risk, with significant favorable outcomes of HER2-low expression compared to HER2-0 in women with high genomic risk.

Topics & Keywords

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Breast

Volume 60, pp. 62-69

DOI: 10.1016/j.breast.2021.08.016

Field-Weighted Citation Impact: 10.02